Current Report Filing (8-k)
10 Janvier 2023 - 10:31PM
Edgar (US Regulatory)
false0000748592MANASDAQ00007485922023-01-092023-01-09
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 9, 2023
Eterna Therapeutics Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
001-11460
|
31-1103425
|
|
(State or
Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
1035 Cambridge
Street, Suite 18A
|
|
|
|
Cambridge,
MA
|
|
02141
|
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code: (212) 582-1199
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each
class
|
|
Trading
symbol
|
|
Name of each
exchange on which registered
|
Common Stock, par value $0.005 per share
|
|
ERNA
|
|
The Nasdaq
Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 3.01 |
Notice of
Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
|
As previously reported, Eterna Therapeutics Inc. (the “Company”) applied on January
2, 2023 to transfer the listing of its common stock, par value
$0.005 per share (the “common stock”), from the
Nasdaq Global Market to The Nasdaq Capital Market (the
“Transfer”).
On
January 9, 2023, the Company received confirmation that the Staff
of Nasdaq had approved the Transfer. As a result, the common
stock will begin trading on The Nasdaq Capital Market effective
with the open of trading on January 11, 2023. The common stock will
continue to trade under the symbol “ERNA”. The Nasdaq Capital
Market operates in substantially the same manner as The Nasdaq
Global Market, with issuers listed on The Nasdaq Capital Market
tier required to meet certain financial and corporate governance
requirements to qualify for continued listing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly authorized.
|
Eterna
Therapeutics Inc.
|
|
|
|
Dated: January 10, 2023
|
By:
|
/s/ Andrew Jackson
|
|
|
Andrew Jackson
|
|
|
Chief Financial Officer
|
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Graphique Historique de l'Action
De Fév 2023 à Mar 2023
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023
